Washington University School of Medicine in St. Louis and BJC Health System have launched the joint Center for Health AI. The center will focus on making care more personalized and effective for ...

Abbott's Freestyle Libre 2 and 3 are the first CGMs to receive FDA clearance for use during imaging tests like X-rays, CT ...

The valuation of Prime Medicine’s stock, supported by a risk-adjusted net present value analysis, underpins the Buy rating, with a 12-month price target set at $10 per share. According to TipRanks, He ...

This Research Topic, "Innovative imaging in neurological disorders: bridging engineering and medicine," seeks to highlight groundbreaking advancements in brain imaging technologies and their ...

Adobe on Tuesday added software tools that let its customers use artificial intelligence to create images based on its ...

Lives will be lost because of a shortage of specialist medicine used to detect diseases such as breast and bowel cancer. That ...

FILE - This April 26, 2017 file photo shows the Eli Lilly & Co. corporate headquarters ... he is keeping his “outperform” rating on the stock. He noted that Lilly “is just getting started in ...

In July, the stock influencer unveiled a 6.6% stake in Chewy, an e-retailer selling pet food and medicine, days after Gill posted a picture of a dog on his X account. Known for his cryptic posts ...

OpenAI is reportedly taking some big steps to diversify and mitigate its reliance on third-party semiconductors. In addition to developing its first in-house AI chip, the company has reportedly ...

H.C. Wainwright has recently initiated Prime Medicine Inc (PRME) stock to Buy rating, as announced on May 20, 2024, according to Finviz. Earlier, on May 16, 2024, Citigroup had raised the stock from a ...

On Monday, Mind Medicine (MindMed) Inc (MNMD) stock saw a modest uptick, ending the day at $6.65 which represents a slight increase of $0.60 or 9.92% from the prior close of $6.05. The stock opened at ...

Disc Medicine's stock performance has been volatile, reflecting the typical nature of biotechnology companies with no approved products yet. The company's market valuation is primarily driven by ...